CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets

Key Points

• Brookline Capital Markets raised its FY2026 EPS estimate for Cognition Therapeutics to a loss of $0.42 per share from a prior forecast of $0.44, though this remains below the consensus estimate of a $0.34 loss.
• Cognition Therapeutics reported a quarterly loss of $0.04 per share, beating analyst expectations of a $0.06 loss.
• CGTX shares opened at $1.02, down 2.9%, while analysts maintain a “Moderate Buy” consensus rating with an average price target of $3.33; institutional investors own 43.35% of the stock.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities research analysts at Brookline Capital Markets raised their FY2026 earnings estimates for shares of Cognition Therapeutics in a report issued on Friday, August 7th. Brookline Capital Markets analyst F. Ahmed now expects that the company will post earnings per share of ($0.42) for the year, up from their prior estimate of ($0.44). The consensus estimate for Cognition Therapeutics' current full-year earnings is ($0.34) per share.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02.

Several other research firms have also weighed in on CGTX. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cognition Therapeutics in a research note on Wednesday, June 24th. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price target on shares of Cognition Therapeutics in a research note on Monday, June 22nd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $3.33.

Cognition Therapeutics Stock Down 2.9%

NASDAQ:CGTX opened at $1.02 on Wednesday. The firm has a market capitalization of $96.99 million, a PE ratio of -6.00 and a beta of 1.77. Cognition Therapeutics has a 12-month low of $0.55 and a 12-month high of $3.83. The firm has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.11.

Institutional Trading of Cognition Therapeutics

Several large investors have recently added to or reduced their stakes in CGTX. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Cognition Therapeutics by 11,695.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company's stock worth $2,781,000 after buying an additional 2,042,815 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Cognition Therapeutics by 105.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company's stock worth $3,620,000 after acquiring an additional 1,377,263 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Cognition Therapeutics in the 2nd quarter worth approximately $1,451,000. Acadian Asset Management LLC grew its position in Cognition Therapeutics by 814.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company's stock worth $422,000 after acquiring an additional 897,353 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in Cognition Therapeutics during the 3rd quarter worth approximately $757,000. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer's disease. The company's lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer's disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source